Low-Carb and Diabetes in the UK: A Safety-First Guide
What the current NHS and NICE evidence says about low-carbohydrate diets for Type 2 diabetes in the UK — including which medications require a review before you change your diet, and why SGLT-2 inhibitors carry a specific risk you must know about.
Low Carb Life
Contributor
Medical disclaimer: This guide is for informational purposes only. It does not constitute medical advice and is not a substitute for guidance from your GP, Diabetes Specialist Nurse, or other qualified healthcare professional. If you take any medication for diabetes — including insulin, sulfonylureas, or SGLT-2 inhibitors — you must speak to your diabetes care team before making significant changes to your carbohydrate intake. Failing to do so carries a risk of serious medical emergencies. The content of this guide reflects current NHS and NICE guidance as of early 2026 and is focused on Type 2 diabetes only.
Millions of people in the UK are managing Type 2 diabetes, and interest in low-carbohydrate diets as a tool for doing so has grown substantially over the past decade. Diabetes UK has conditionally endorsed carbohydrate restriction for adults with Type 2 diabetes who are overweight. NHS England now funds programmes specifically aimed at achieving diabetes remission through dietary intervention.
But this is also an area where the wrong approach — particularly around medication — can cause serious harm.
This guide sets out what the current evidence actually says, which medications create specific risks when you reduce carbohydrates, and what questions to ask your GP or diabetes care team before you start.
This guide is for Type 2 diabetes only
The safety considerations for low-carbohydrate diets differ fundamentally between Type 1 and Type 2 diabetes, and treating them as the same is dangerous.
Type 2 diabetes is primarily characterised by insulin resistance and a relative reduction in insulin production, heavily linked to excess weight and metabolic dysfunction. Reducing dietary carbohydrate directly lowers the glucose load on the body, which can improve blood sugar control and support weight loss.
Type 1 diabetes is an autoimmune condition in which the pancreas produces no insulin at all. Patients are entirely dependent on injected or pumped insulin for survival. Both Diabetes UK and the British Dietetic Association (BDA) are explicit: they do not recommend low-carbohydrate diets for Type 1 diabetes management outside of closely supervised clinical settings. The risks of unpredictable hypoglycaemia and the complexity of adjusting insulin to a high-protein, high-fat diet require specialist oversight that is not appropriate to navigate through a general-purpose guide.
If you have Type 1 diabetes and are interested in carbohydrate reduction, please raise this directly with your diabetes consultant or specialist nurse rather than using this guide.
How the UK defines a low-carbohydrate diet
The NHS and Diabetes UK use a clear grammage-based definition:
| Dietary approach | Carbohydrates per day |
|---|---|
| Typical Western diet | Over 230g |
| Moderate carbohydrate | 130g to 230g |
| Low-carbohydrate (LCD) | Under 130g |
| Very low-carbohydrate / ketogenic | 20g to 50g |
Diabetes UK defines a low-carbohydrate diet as consuming under 130g of carbohydrates per day. This is the threshold used in clinical recommendations and NHS-commissioned programmes.
The charity explicitly states that carbohydrates should not be eliminated entirely — specific carbohydrate-containing foods provide vitamins, minerals, and fibre that matter for long-term cardiovascular and gut health.
The ketogenic range (20–50g per day) goes significantly further than the Diabetes UK-endorsed threshold. While it may produce more rapid results for some people, it also carries meaningfully higher risks — particularly for people on certain medications — and is not what most UK clinical guidance refers to when it recommends “low-carbohydrate” approaches.
What NICE and Diabetes UK currently say
The primary NHS clinical guideline for Type 2 diabetes management is NICE NG28, which was updated in February 2026.
NICE does not prescribe a single dietary approach for all patients. Its guidance emphasises individualised care tailored by healthcare professionals with nutrition expertise. It encourages high-fibre, low-glycaemic-index sources of carbohydrate — vegetables, wholegrains, pulses — rather than blanket elimination.
For weight management and the possibility of diabetes remission, NICE directs clinicians to refer eligible patients to the NHS Type 2 Diabetes Path to Remission Programme (more on this below). Importantly, the updated NG28 guidance explicitly references patients choosing low-carbohydrate or ketogenic diets, and mandates that clinicians are vigilant about medication risks when this happens — effectively acknowledging that carbohydrate restriction is a legitimate and common patient choice.
Diabetes UK’s current position conditionally supports lower-carbohydrate diets (50–130g per day) as an effective short-term intervention for adults with Type 2 diabetes who are overweight or obese. The evidence shows meaningful benefits for weight loss, HbA1c reduction, and cardiovascular risk factors. However, the charity notes there is no consistent evidence that low-carb is more effective than other dietary approaches in the long term, and it should be viewed as one of several valid options rather than the only path.
The evidence: what UK research actually shows
The DiRECT trial
The DiRECT trial is the most influential UK-based study on Type 2 diabetes remission, and it is frequently cited by low-carbohydrate advocates. It is important to understand what it actually studied.
DiRECT did not investigate a low-carbohydrate diet. It used Total Diet Replacement (TDR): specially formulated soups and shakes providing 800–900 calories per day for 12 weeks, with a macronutrient profile that remained at approximately 50% carbohydrate. Its mechanism was severe caloric restriction and the resulting weight loss, not carbohydrate restriction specifically.
The results were clinically significant: at one year, 46% of participants achieved remission. Of those who lost 15kg or more, 86% put their Type 2 diabetes into remission. Weight loss was the primary driver.
However, the 5-year follow-up data tells a sobering story. By year five, only 10% of the intervention group remained in remission, compared to 5% of the control group. Average weight loss had fallen to 5.6kg as weight was gradually regained. Remission is achievable; maintaining it long-term is genuinely difficult.
The NHS Type 2 Diabetes Path to Remission Programme
Directly scaling the DiRECT methodology, the NHS now fully funds a 12-month programme for eligible patients. It provides 12 weeks of low-calorie meal replacement soups and shakes (800–900 kcal per day), followed by structured food reintroduction and long-term behavioural support. Over 13,000 patients enrolled in the 2024–2025 financial year.
This is a low-calorie programme, not a low-carbohydrate one. The distinction matters for medication management.
Second Nature (formerly the Low Carb Program)
This NHS-commissioned digital programme originally focused on strict carbohydrate restriction and has real-world peer-reviewed evidence behind it. A 2024 JMIR evaluation of 1,130 participants found that engaged users achieved a mean weight loss of 13.8kg at two years. The programme has since evolved toward a moderate lower-carbohydrate approach of around 45–60g of carbohydrates per day — an intentional design decision to improve long-term sustainability compared to strict ketogenic restriction. It is widely available via GP referral.
The Virta Health study
Virta is a US-based, continuously monitored ketogenic intervention (under 30g of carbohydrates per day) that is extensively cited in low-carbohydrate literature. Its reported outcomes are impressive — significant HbA1c reduction, weight loss, and high rates of medication deprescription.
From the perspective of UK evidence standards, however, it has notable limitations: participants self-selected into the programme, introducing selection bias, and attrition was high. Virta’s results reflect highly motivated, continuously supervised individuals. This does not diminish what it demonstrates is physiologically possible, but it does limit its applicability as a blanket recommendation within the NHS framework.
Medications and safety: the most important section of this guide
Reducing dietary carbohydrate changes how your body manages blood glucose. If you take medications that actively lower blood glucose, continuing them at the same dose while reducing carbohydrate intake can cause dangerously low blood sugar — or, with one specific class of medication, a potentially life-threatening complication that standard glucose testing will not detect.
This is not a theoretical risk. UK clinical guidelines are explicit about it.
Understanding hypoglycaemia (a hypo)
In UK clinical practice, hypoglycaemia is defined as blood glucose falling below 4.0 mmol/L.
Symptoms include intense hunger, sweating, shaking, palpitations, anxiety or irritability, dizziness, tingling lips, blurred vision, and confusion. Severe hypoglycaemia can progress to seizures and loss of consciousness and requires emergency intervention.
The standard NHS first response to a hypo in a conscious person is 15–20g of fast-acting carbohydrate: five glucose tablets, four large jelly babies, or 150ml of pure fruit juice. Blood glucose should be retested after 10–15 minutes, and a longer-acting carbohydrate snack consumed once levels are safely above 4.0 mmol/L.
High-risk medications: speak to your GP before changing your diet
Insulin (all types) Basal (long-acting), bolus (rapid-acting), and pre-mixed insulins directly drive glucose into cells regardless of what you have eaten. If carbohydrate intake drops significantly but insulin doses remain unchanged, severe hypoglycaemia will follow. Insulin doses must be reviewed and proactively adjusted by your diabetes care team before you begin.
Sulfonylureas This class of oral medication — including gliclazide (Diamicron), glipizide, and glibenclamide — works by forcing the pancreas to secrete insulin continuously, regardless of your blood glucose level. They do not respond to how much you have eaten. If carbohydrate intake drops while you remain on a sulfonylurea at your existing dose, the risk of prolonged, severe hypoglycaemia is significant, particularly in older people or those with kidney impairment.
Prandial glucose regulators (glinides) Repaglinide (Prandin) and nateglinide (Starlix) stimulate a rapid, short-burst insulin secretion intended to cover the glucose spike from a meal. If a meal contains no carbohydrates but the medication is still taken, a rapid hypo is highly likely.
Lower-risk medications — but still discuss with your GP
The following medications lower blood glucose through mechanisms that are glucose-dependent or do not stimulate insulin secretion directly. The immediate hypoglycaemia risk is lower when taken as monotherapy, but your overall glycaemic profile will still change as your diet changes, and your GP or diabetes nurse should be aware.
Metformin reduces the liver’s release of stored glucose and improves insulin sensitivity. It does not stimulate insulin secretion, so hypoglycaemia risk as a monotherapy is negligible.
GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, liraglutide, dulaglutide/Trulicity) stimulate insulin release only when blood glucose is already elevated — they switch off when glucose is normal. Hypo risk is very low unless combined with insulin or a sulfonylurea.
DPP-4 inhibitors / gliptins (sitagliptin, alogliptin, linagliptin) work by a similar glucose-dependent mechanism and carry a similarly low standalone hypo risk.
SGLT-2 inhibitors: a specific, serious risk you must know about
This section is the most important safety information in this guide.
SGLT-2 inhibitors — empagliflozin (Jardiance), dapagliflozin (Forxiga), canagliflozin (Invokana), and ertugliflozin (Steglatro) — lower blood glucose by blocking glucose reabsorption in the kidneys, causing excess glucose to be excreted in the urine.
As of the February 2026 update to NICE NG28, SGLT-2 inhibitors have been elevated to first-line treatment for Type 2 diabetes patients with chronic kidney disease, heart failure, or established cardiovascular disease. They are being prescribed to a rapidly growing number of people in the UK.
The specific risk: euglycaemic diabetic ketoacidosis (euDKA)
SGLT-2 inhibitors alter metabolism in a way that naturally promotes fat burning and ketone production. If a patient on an SGLT-2 inhibitor adopts a very low-carbohydrate or ketogenic diet, the combined effect — drug-driven glucose excretion plus severely restricted carbohydrate intake — can trigger an uncontrolled overproduction of acidic ketone bodies, causing Diabetic Ketoacidosis (DKA).
DKA is a medical emergency.
What makes this particularly dangerous is the word “euglycaemic” — because the SGLT-2 inhibitor continues to excrete glucose in the urine, your blood glucose reading on a standard finger-prick test may appear completely normal. A normal blood sugar result will not tell you that DKA is occurring.
The MHRA (the UK medicines regulator) and NHS prescribing guidelines explicitly list adherence to a low-carbohydrate or ketogenic diet as a high-risk factor for DKA while taking SGLT-2 inhibitors. Updated NICE NG28 guidance states that patients wishing to attempt a ketogenic diet must be warned about this risk and must discuss it with a healthcare professional before starting.
Symptoms of DKA — seek urgent medical attention if you experience these, regardless of what your glucose monitor shows:
- Extreme thirst and frequent urination
- Nausea and vomiting
- Abdominal pain
- Deep, rapid breathing
- Fruity-smelling breath
- Confusion or difficulty concentrating
If you are taking an SGLT-2 inhibitor and are considering a significant reduction in carbohydrate intake, this is not a conversation to defer. Speak to your GP or diabetes nurse first.
Before you start: what to discuss with your GP or diabetes team
UK clinical guidelines are unambiguous: any person taking glucose-lowering medication should have a comprehensive medication review before significantly restricting dietary carbohydrates.
This should be with your GP, Diabetes Specialist Nurse (DSN), or appropriately trained practice nurse. The review is not a formality — it is the mechanism by which medication doses can be proactively reduced to match your lower dietary glucose load, preventing emergencies before they happen.
Helpful questions to raise:
- Do any of my current medications carry a hypoglycaemia risk if I reduce my carbohydrate intake?
- I am considering a low-carbohydrate diet — is there anything about my current medication combination I should be aware of?
- If I am on an SGLT-2 inhibitor, what do I need to know about ketogenic diets and DKA risk?
- Should my medication be reviewed or adjusted before I start?
- How often should I be monitoring my blood glucose while making this dietary change?
- What should I do if I experience symptoms of a hypo?
What the evidence says about foods
Diabetes UK’s dietary guidance emphasises whole, unprocessed foods with a low glycaemic index. Foods that work well for blood glucose management include:
Well-supported choices: Non-starchy vegetables (broccoli, spinach, courgette, leeks, mushrooms, aubergine), eggs, oily fish, poultry and unprocessed meat, unsalted nuts, full-fat Greek or natural yogurt, and cheese.
Foods that cause rapid blood glucose spikes: Refined carbohydrates (white bread, white rice, standard pasta, pastry, processed breakfast cereals), sweets, cakes, and sugary drinks.
A specific warning on fruit juice: Diabetes UK and the NHS explicitly caution against fruit juice for people managing blood glucose. The juicing process destroys the fibre that normally slows sugar absorption — the fructose from a glass of orange juice enters the bloodstream rapidly and causes a significant, immediate glucose spike. Whole fruit in moderation is a different matter; juice is not.
“Diabetic” foods: UK guidance strongly advises against foods marketed specifically as “diabetic” (diabetic chocolate, diabetic sweets). They offer no clinical benefit, are often high in calories, and the sugar alcohols used as sweeteners frequently cause gastrointestinal distress.
NHS support and resources
NHS Type 2 Diabetes Path to Remission Programme A fully funded 12-month programme using total diet replacement (800–900 kcal soups and shakes for 12 weeks, followed by supported food reintroduction). Available via GP referral to eligible patients. Ask your GP whether you qualify.
Second Nature (formerly the Low Carb Program) An NHS-commissioned digital behaviour change programme with HCPC-registered dietitian access, available via GP referral across many Integrated Care Boards. Takes a moderate lower-carbohydrate approach of approximately 45–60g of carbohydrates per day.
DESMOND The national structured education programme for Type 2 diabetes. Primarily covers carbohydrate awareness and healthy eating. Has recently issued a position statement supporting patients who choose low-carbohydrate options for weight management.
Continuous Glucose Monitoring (CGM) CGM devices (such as the FreeStyle Libre 2 Plus, Libre 3, or Dexcom models) are now available on NHS prescription for all adults with Type 1 diabetes, and for adults with Type 2 diabetes who use multiple daily insulin injections or meet specific criteria. A CGM shows exactly how your blood glucose responds to different foods — one of the most useful tools available if you are exploring carbohydrate reduction.
Diabetes UK Diabetes UK provides an online Learning Zone, peer support forums, dietitian-approved low-carb recipes and meal plans, and a clinical helpline. Their resources are specifically tailored to UK palates and supermarket availability: diabetes.org.uk
On remission: what it means and what it does not mean
“Remission” is the only clinically accepted term for what some people call “reversing” or “curing” Type 2 diabetes. Both of those words should be avoided — they imply a permanent resolution that the evidence does not support.
The internationally agreed clinical definition of remission, formally adopted by Diabetes UK, the BDA, and the European Association for the Study of Diabetes in 2021, is:
An HbA1c below 6.5% (48 mmol/mol) that persists for at least three months in the complete absence of any glucose-lowering medication.
Remission is not a permanent cure. The underlying susceptibility to Type 2 diabetes remains. The DiRECT trial 5-year data shows that most people who achieve remission eventually relapse as weight is gradually regained. Remission requires ongoing vigilance.
Critically, even in remission, you should continue to attend your annual NHS diabetes reviews — retinal screening, foot checks, kidney function tests — because the long-term metabolic effects of previous hyperglycaemia still carry risks for complications that do not simply disappear.
A note on what this guide does not claim
The evidence for low-carbohydrate diets in Type 2 diabetes management is meaningful and growing. But the evidence does not show that low-carb is the best or only approach for everyone.
Long-term systematic reviews do not demonstrate that low-carbohydrate diets are clinically superior to other well-formulated dietary approaches — such as the Mediterranean diet — when calories are matched and adherence is sustained. The most effective diet for managing Type 2 diabetes is ultimately the one a person can maintain over years, not the one that produces the best results in a 12-week trial.
Low-carbohydrate eating is a well-evidenced option. It is not a universal prescription.
This guide will be reviewed and updated when NICE NG28 guidance or Diabetes UK position statements are materially updated. Last reviewed: March 2026. If you have concerns about anything covered here, please speak to your GP or diabetes care team.
Some links in this article may be affiliate links. If you buy through them, we may earn a small commission at no extra cost to you — it helps keep this site free. We only ever link to products we’d actually use.